HANSHOW
8.11.2021 07:27:11 CET | Business Wire | Press release
At the 2021 China International Import Expo (CIIE), Hanshow has announced a commercial AI camera-driven retail solution, developed through a collaboration with Microsoft and Sony Semiconductor Solutions Corporation (Sony). This solution combines Sony’s intelligent vision sensor IMX500, the world’s first image sensor equipped with AI functionality, with Microsoft Azure and its AI capabilities to achieve AI processing on edge. As part of the Partner Enablement Program through Microsoft AI & IoT Insider Labs, Microsoft Global ISV Hanshow continues to upgrade its intelligent solution to better serve its global customers especially in the retail industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211107005144/en/
In a busy retail setting, staff are often unable to complete timely and accurate monitoring of product shelf status. This results in products being out-of-stock, improperly arranged, lost sales, unsatisfied customers, and unattractive store appearance. Meanwhile, customer flow analysis is crucial for retailers to better understand customer behavior in their stores including traffic, visited areas, customer paths, dwell time and loyalty.
Hanshow’s AI retail solution monitors out-of-stock occurrences along with product volume status, customer traffic flows, sales levels, and other store information. This not only allows for real time out-of-stock notifications, but also stores and analyzes data over time to help managers optimize operations and displays.
This upgraded AI retail solution involves Hanshow’s AI calculations (product recognition), digital advertising technology with media content at the shelf based on the Azure AI and IoT platform with data collection and analysis from Sony’s IMX 500 intelligent vision sensor. This also opens new sales opportunities for retailers and creates more customer behavior data to help drive targeted advertising.
The sensor outputs metadata (semantic information belonging to image data) instead of image information, that helps in reducing data traffic and addressing privacy concerns by not collecting personal information. A similar Hanshow solution is already in use at supermarket settings. One major supermarket chain saw a near 50% reduction in out-of-stock time by using similar AI technology.
This solution and three-party collaboration was born out of Microsoft’s Partner Enablement Program which enriches existing tech ecosystems by recruiting qualified partners with experiences, sales and marketing resources to accelerate their time to market through the Microsoft AI & IoT Insider Labs.
Hanshow’s experience in global retail markets, combined with the technological support from Microsoft and Sony “can accelerate co-innovation initiatives to better serve the rapidly changing and diversified retail industry, helping retailers to be more agile and profitable. We are also exploring application of this solution in manufacturing and other industries together with Microsoft and Sony.” said Shiguo Hou, the CEO of Hanshow.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. As an innovation leader in the industry, Hanshow is dedicated to offering its global customers a series of world-class customized IoT touchpoints and digital store solutions. Hanshow’s intelligence-enabled platforms and systems deliver customer-centric insights, helping retailers streamline operations and providing various solutions to support optimal pricing strategies to offer consumers a more personalized experience. Hanshow currently serves over 20,000 stores in more than 50 countries. Contact Hanshow: https://www.hanshow.com/Form.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20211107005144/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
